!!Urs Meyer

__Activities__
\\	 
*1981 - 1991	National Research Council, Swiss National Science Foundation
*1988 - 1992	Advisory Board, Robert Bosch Stiftung, Stuttgart, Germany
*1989 - 1991	President, Clinical Section, Division of Biology and Medicine, Swiss National Science Foundation
*1989 - 1996	Member of the Board of Trustees, Sandoz Foundation for Gerontological Research, Basel.
*1994 - 1998	Scientific Council, International Agency for Research on Cancer (IARC), WHO, Lyon, France
*1997 - 2000	Swiss Board of Consultants, Basel Institute for Immunology
*2000 -	Co-editor Pharmacogenomics, Faculty 1000
*2010 - 2011	President, International Society for the Study of Xenobiotics
*2012 - 2015	President, European Center for Pharmaceutical Medicine Foundation
\\  
__Editor__	
\\
*Associate Editor, Annual Reviews of Pharmacology and Toxicology (2015- )
*Editor-in-Chief, Journal of Personalized Medicine ( 2011- 2014)
*Co-Editor “pharma-kritik”
*Co-Editor, Progress in Drug Research (1986 - 1988)
*Co-Editor, Advances in Drug Research (1993 - 1997)
 \\	 
__Editorial boards__	
\\
*European Journal of Clinical Pharmacology (1985 - 2000)
*Clinical Pharmacology and Therapeutics (1986 - 1998)
*Thérapie (1990 - )
*Hepatology (1991 - 1997)
*Journal of Molecular Medicine (1994 - 2002)
*Pharmacogenetics & Genomics (1991 - )
*Molecular Diagnosis & Therapy (2000 - )
*Annual Review of Pharmacology & Toxicology (2005 -)
*Drug Metabolism and Drug Interactions , now Drug Metabolism and
*Personalized Therapy (2010 - )
\\ 
__Publications__	
\\
*> 330; h-index 93, > 30’000 citations (Google Scholar 2018)
\\ 
__Patents__
\\
#US Patent 07/845, 507 (Coinventor) "Method for identifying humans with genetic defects in drug metabolism"\\
#US Patent Nr. 5,648,482 "Primers targeted to CYP2D6 gene for detecting poor metabolizers of drugs"
\\
__License agreement__
\\
*BD-Biosciences, Woburn, USA
\\ 
__Other activities	__
\\
*Scientific advisor for various biotech and pharma companies
*Board of Directors, PharmaSens AG